Shengzhe Ding, Yu-Jin Kim, Kai-Yu Huang, Daniel Um, Youngmee Jung, Hyunjoon Kong
{"title":"Delivery-mediated exosomal therapeutics in ischemia–reperfusion injury: advances, mechanisms, and future directions","authors":"Shengzhe Ding, Yu-Jin Kim, Kai-Yu Huang, Daniel Um, Youngmee Jung, Hyunjoon Kong","doi":"10.1186/s40580-024-00423-8","DOIUrl":null,"url":null,"abstract":"<div><p>Ischemia-reperfusion injury (IRI) poses significant challenges across various organ systems, including the heart, brain, and kidneys. Exosomes have shown great potentials and applications in mitigating IRI-induced cell and tissue damage through modulating inflammatory responses, enhancing angiogenesis, and promoting tissue repair. Despite these advances, a more systematic understanding of exosomes from different sources and their biotransport is critical for optimizing therapeutic efficacy and accelerating the clinical adoption of exosomes for IRI therapies. Therefore, this review article overviews the administration routes of exosomes from different sources, such as mesenchymal stem cells and other somatic cells, in the context of IRI treatment. Furthermore, this article covers how the delivered exosomes modulate molecular pathways of recipient cells, aiding in the prevention of cell death and the promotions of regeneration in IRI models. In the end, this article discusses the ongoing research efforts and propose future research directions of exosome-based therapies.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":712,"journal":{"name":"Nano Convergence","volume":"11 1","pages":""},"PeriodicalIF":13.4000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://nanoconvergencejournal.springeropen.com/counter/pdf/10.1186/s40580-024-00423-8","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano Convergence","FirstCategoryId":"88","ListUrlMain":"https://link.springer.com/article/10.1186/s40580-024-00423-8","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Ischemia-reperfusion injury (IRI) poses significant challenges across various organ systems, including the heart, brain, and kidneys. Exosomes have shown great potentials and applications in mitigating IRI-induced cell and tissue damage through modulating inflammatory responses, enhancing angiogenesis, and promoting tissue repair. Despite these advances, a more systematic understanding of exosomes from different sources and their biotransport is critical for optimizing therapeutic efficacy and accelerating the clinical adoption of exosomes for IRI therapies. Therefore, this review article overviews the administration routes of exosomes from different sources, such as mesenchymal stem cells and other somatic cells, in the context of IRI treatment. Furthermore, this article covers how the delivered exosomes modulate molecular pathways of recipient cells, aiding in the prevention of cell death and the promotions of regeneration in IRI models. In the end, this article discusses the ongoing research efforts and propose future research directions of exosome-based therapies.
缺血再灌注损伤(IRI)给心脏、大脑和肾脏等多个器官系统带来了重大挑战。外泌体通过调节炎症反应、增强血管生成和促进组织修复,在减轻 IRI 引起的细胞和组织损伤方面显示出巨大的潜力和应用前景。尽管取得了这些进展,但更系统地了解不同来源的外泌体及其生物转运对于优化疗效和加快临床采用外泌体进行 IRI 治疗至关重要。因此,本文综述了间充质干细胞和其他体细胞等不同来源的外泌体在IRI治疗中的给药途径。此外,本文还介绍了外泌体如何调节受体细胞的分子通路,从而在IRI模型中帮助预防细胞死亡和促进再生。最后,本文讨论了正在进行的研究工作,并提出了基于外泌体疗法的未来研究方向。 图文摘要
期刊介绍:
Nano Convergence is an internationally recognized, peer-reviewed, and interdisciplinary journal designed to foster effective communication among scientists spanning diverse research areas closely aligned with nanoscience and nanotechnology. Dedicated to encouraging the convergence of technologies across the nano- to microscopic scale, the journal aims to unveil novel scientific domains and cultivate fresh research prospects.
Operating on a single-blind peer-review system, Nano Convergence ensures transparency in the review process, with reviewers cognizant of authors' names and affiliations while maintaining anonymity in the feedback provided to authors.